Oncomatryx

Description

Oncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid tumors and offering clinical trial information for researchers and patients.

Related

• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• TILT BiotherapeuticsTILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
• Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
• Orakl OncologyOrakl Oncology builds an AIxBio engine that analyzes multimodal patient data and living biological samples to predict drug responses,…
• NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…